Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclopropyl-methoxycarbonyl metomidate
- Development stage
- Unknown
- Lead developer
- Paion
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Cyclopropyl-methoxycarbonyl metomidate (CPMM) is an experimental, ultra-short-acting intravenous anesthetic and sedative agent. It is a "soft-drug" analogue of metomidate (the methyl ester of etomidate), designed to undergo rapid hydrolysis by non-specific tissue esterases into an inactive carboxylic acid metabolite. This metabolic design aims to combine the favorable hemodynamic stability characteristic of etomidate and metomidate with a rapid recovery profile, while specifically avoiding the sustained adrenocortical suppression (inhibition of 11β-hydroxylase) that typically limits the use of etomidate for continuous infusion. CPMM acts as a positive allosteric modulator of the GABAA receptor, facilitating inhibitory neurotransmission in the central nervous system. It has been investigated in clinical trials for the induction and maintenance of general anesthesia and for procedural sedation.
- Other names
- cyclopropyl-methoxycarbonyl metomidate
02
Targets
CYP11B2 (Cytochrome P450 11B2)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on cyclopropyl-methoxycarbonyl metomidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclopropyl-methoxycarbonyl metomidate.